ASH 2023

Advertisement
Rob DillardConference Coverage | December 12, 2023
Researchers sought to describe the clinical and sociodemographic characteristics of AYA patients with CLL.
Read More
Rob DillardConference Coverage | December 12, 2023
Patients who received CLL/SLL-directed therapies had a lower risk of Richter transformation.
Rob DillardConference Coverage | December 12, 2023
The prevalence of BTK C481 mutations might be higher in CLL patients with longer BTKi exposure.
Rob DillardConference Coverage | December 12, 2023
Venetoclax induces a distinct and prominent transcriptional response in patients with chronic lymphocytic leukemia.
Advertisement
Advertisement
Latest News

April 18, 2025